IRCT20200825048515N77 IRCT 2024-12-15 Esfahan University of Medical Sciences Protective effect of Silymarin on liver during cardiac surgery Protective effect of Silymarin on liver during coronary artery bypass surgery 2025-01-04 anticipated 80 Complete https://irct.ir/trial/80661 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, 80 eligible patients are randomly selected. For this, the letter A is written on 40 sheets, and the letter B is written on 40 sheets and each of them is placed in an envelope. Each patient is then asked to choose one of the envelopes. Depending on the selected envelope, the patient is assigned to one of two groups, Blinding description: In order to achieve the triple-blind study, a placebo drug similar in color, shape, and odor to silymarin will be prepared by the pharmacist before the study begins, and the two drugs will be coded with labels A and B and made available to the researcher. He also prescribes the drugs without knowing the type of medication. In addition, the patient, the person collecting the data, and the statistician will have no knowledge of the type of intervention. 3 Coronary artery bypass surgery. Intervention 1: Intervention group: Patients will receive 6 mg/kg of silymarin daily from one week before surgery with the brand name Livergol, manufactured by Gol Daru Company, each tablet containing 140 mg of silymarin (as 2 mg/kg three times a day). Intervention 2: Control group: Patients will receive placebo daily from one week before surgery. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information